Esperion to Report First Quarter 2021 Financial Results May 4, 2021
April 12 2021 - 4:01PM
Esperion (NASDAQ: ESPR), today announced it will report first
quarter 2021 financial results after the close of the U.S.
financial markets on Tuesday, May 4, 2021.
Following the release, company management will host a webcast
and conference call at 4:30 p.m. ET to discuss financial results
and business progress. The call can be accessed by dialing (877)
831-3840 (domestic) or (253) 237-1184 (international) five minutes
prior to the start of the call and providing the access code
6373518.
A live audio webcast can be accessed on the investor and media
section of the Esperion website at investor.esperion.com. Access to
the webcast replay will be available approximately two hours after
completion of the call and will be archived on the Company's
website for approximately 90 days.
Esperion Therapeutics
ESPERION is The Lipid Management Company. Our goal is lipid
management for everybody, that’s why we work hard to make our
medicines easy to get, easy to take and easy to have. We discover,
develop and commercialize innovative medicines and combinations to
lower cholesterol, especially for patients whose needs aren’t being
met by the status quo. Our entrepreneurial team of industry leaders
is inclusive, passionate and resourceful. We are singularly focused
on managing cholesterol so you can improve your health easily. For
more information, please visit www.esperion.com and follow us on
Twitter at www.twitter.com/EsperionInc.
ESPERION Therapeutics’ Commitment to Patients with
Hyperlipidemia
High levels of LDL-C can lead to a build-up of fat and
cholesterol in and on artery walls (known as atherosclerosis),
potentially leading to cardiovascular events, including heart
attack and stroke. In the U.S., 96 million people, or more than 37
percent of the adult population, have elevated LDL-C. There are
approximately 18 million people in the U.S. living with elevated
levels of LDL-C despite taking maximally tolerated lipid-modifying
therapy — including individuals considered statin averse — leaving
them at high risk for cardiovascular events1. In the United States,
more than 50 percent of atherosclerotic cardiovascular disease
(ASCVD) patients and heterozygous familial hypercholesterolemia
(HeFH) patients who are not able to reach their guideline
recommended LDL-C levels with statins alone need less than a 40
percent reduction to reach their LDL-C threshold goal2.
ESPERION's mission as the Lipid Management Company is to deliver
oral, once-daily medicines that complement existing oral drugs to
provide the additional LDL-C lowering that these patients need.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding commercialization
plans for bempedoic acid tablet and the bempedoic acid/ezetimibe
fixed dose combination tablet. Any express or implied statements
contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements.
Forward-looking statements involve risks and uncertainties that
could cause Esperion's actual results to differ significantly from
those projected, including, without limitation, delays or failures
in Esperion’s clinical development and commercialization plans, or
approval of expanded indications, that existing cash resources may
be used more quickly than anticipated, the impact of COVID-19 on
our business, clinical activities and commercial development plans,
and the risks detailed in Esperion's filings with the Securities
and Exchange Commission. Any forward-looking statements contained
in this press release speak only as of the date hereof, and
Esperion disclaims any obligation or undertaking to update or
revise any forward-looking statements contained in this press
release, other than to the extent required by law.
References
(1) ESPERION market research on file: research project
interviewing 350 physicians. ESPERION Therapeutics, Inc. Sept-Oct
2018.
(2) Data on file: analysis of NHANES database. ESPERION
Therapeutics, Inc. 2018.
Investor Contact:Kaitlyn
BroscoEsperioncorporateteam@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024